Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124,058,172
-
Total 13F shares
-
27,996,605
-
Share change
-
+6,668,082
-
Total reported value
-
$919,180,783
-
Price per share
-
$32.99
-
Number of holders
-
51
-
Value change
-
+$216,834,869
-
Number of buys
-
36
-
Number of sells
-
11
Institutional Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q3 2020
As of 30 Sep 2020,
ADC Therapeutics SA - Common Shares (ADCT) was held by
51 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
27,996,605 shares.
The largest 10 holders included
FMR LLC, Redmile Group, LLC, JPMORGAN CHASE & CO, BAKER BROS. ADVISORS LP, Magnetar Financial LLC, Grosvenor Holdings, L.L.C., ALLIANCEBERNSTEIN L.P., PRICE T ROWE ASSOCIATES INC /MD/, EVENTIDE ASSET MANAGEMENT, LLC, and MPM ONCOLOGY IMPACT MANAGEMENT LP.
This page lists
50
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.